drugset

Drugs / NGM621

Follow last change Nov 2022 re-read 3 minutes ago

NGM621

Developed for: diffuse secondary choroid atrophy · COVID-19
Investigated by: NGM Biopharmaceuticals, Inc

Trials 3

today NCT04582318 · Ph 1/2 NCT04465955 · Ph 2 NCT04014777 · Ph 1

2020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT04014777	Jul 2019 → May 2020	diffuse secondary choroid atrophy	NGM Biopharmaceuticals, Inc	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT04582318	Nov 2020 → Feb 2021	COVID-19	NGM Biopharmaceuticals, Inc	Terminated	No outcome recorded
Phase 21 trial · 1 missed
Phase 2	NCT04465955	Jul 2020 → Aug 2022	diffuse secondary choroid atrophy	NGM Biopharmaceuticals, Inc	Completed	Missed primary

News releases announcing trial results or a regulatory action · 5

Date	Issuer	Release
2022-11-03	NGM Biopharmaceuticals, Inc	Results NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results ngmbio.com ↗
2022-11-03	NGM Biopharmaceuticals, Inc	Results NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting ngmbio.com ↗
2022-10-17	NGM Biopharmaceuticals, Inc	Results NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration ngmbio.com ↗
2022-02-07	NGM Biopharmaceuticals, Inc	Regulatory NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration ngmbio.com ↗
2020-11-13	NGM Biopharmaceuticals, Inc	Results NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual ngmbio.com ↗ Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study, with no patients experiencing serious adverse events, drug-related AEs, intraocular inflammation or choroidal neovascularization

All press releases naming this drug 10 releases

Date	Issuer	Release
2022-11-03	NGM Biopharmaceuticals, Inc	NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results ngmbio.com ↗
2022-11-03	NGM Biopharmaceuticals, Inc	NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting ngmbio.com ↗
2022-10-17	NGM Biopharmaceuticals, Inc	NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration ngmbio.com ↗
2022-10-16	NGM Biopharmaceuticals, Inc	NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration ngmbio.com ↗
2022-02-07	NGM Biopharmaceuticals, Inc	NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration ngmbio.com ↗
2021-07-22	NGM Biopharmaceuticals, Inc	NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration ngmbio.com ↗
2021-02-09	NGM Biopharmaceuticals, Inc	NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition ngmbio.com ↗
2020-11-13	NGM Biopharmaceuticals, Inc	NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual ngmbio.com ↗
2020-11-05	NGM Biopharmaceuticals, Inc	NGM Bio to Present Safety and Pharmacokinetics Data from Phase 1 Study of NGM621 in Patients with Geographic Atrophy at American Academy of Ophthalmology (AAO) 2020 Virtual ngmbio.com ↗
2020-07-27	NGM Biopharmaceuticals, Inc	NGM Bio Announces Initiation of Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) ngmbio.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	NGM621	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04465955 ↗ 2 NCT04582318 ↗ NCT04014777 ↗
Route	Intravitreal	“Intravitreal Injections of NGM621” NCT04014777 ↗